NCT05988814招募中2 期
Phase II Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy (FOLFIRINOX3 Pancréas)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
Evaluate the efficacy of treatment FOLFORINOX 3 in first-line therapy for patients with locally advanced unresectable or metastatic pancreatic cancer.
详细描述
Evaluate the efficacy of treatment FOLFORINOX 3 in first-line therapy for patients with locally advanced unresectable or metastatic pancreatic cancer.
Treatment with FOLFIRINOX3 will be administered with a maximum of 16 courses divided into two 8-course doses. Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female age > 18 years at time of study entry
- •Performance status of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG)
- •Patients with pancreatic adenocarcinoma
- •Patients with unresectable locally advanced pancreatic cancer or metastatic pancreatic cancer
- •Patients with no history of chemotherapy (prior adjuvant or neoadjuvant chemotherapy accepted if the time between the end of chemotherapy and recurrence is greater than 12 months) and no history of curative radiotherapy for metastatic or locally advanced disease. Palliative radiotherapy is accepted.
- •Patient eligible for treatment with FOLFIRINOX (5-FU, Irinotecan, Oxaliplatin and folinic acid) including but not limited to: No active heart disease An ECG with a QT/QTc interval ˂ to 450 ms for men and ˂ to 470 ms for women. No uncontrolled hypertension defined by systolic pressure > 140 mmHg or diastolic pressure > 90 mmHg despite optimal medical management. A negative pregnancy test if applicable
- •Tumor evaluation (CT scan) performed within 4 weeks (28 days) prior to inclusion with at least one measurable lesion according to RECIST 1.1 criteria
- •Patient fit and able to comply with the protocol for the duration of the study, including treatment, visits, scheduled examinations and follow-up.
- •Biological, hepatic, renal and serological data within the following limits (tests performed within 7 days of inclusion except for serologies performed within 28 days)
- •Information given and informed consent signed
- •Patient affiliated to a social security scheme
- •Men and women must have an effective contraceptive method.
排除标准
- •Patient with neuroendocrine carcinoma or acinar cell carcinoma
- •Other cancer in the 5 years preceding inclusion or concomitant (except cancer in situ of the uterine cervix or cutaneous basal cell carcinoma).
- •Presence of brain metastasis(es)
- •Estimated prognosis < 3 months
- •History of grade 4 toxicity to oxaliplatin, irinotecan or 5FU if history of adjuvant/neoadjuvant chemotherapy
- •Sequellar toxicity > grade 1 if previous adjuvant/neoadjuvant chemotherapy
- •Hypersensitivity to any component of FOLFIRINOX® treatment.
- •Current participation or participation within 30 days prior to inclusion in another therapeutic trial with an investigational compound and/or completion of radiotherapy within 10 days prior to the start of treatment
- •Evidence of a homozygous or heterozygous DPYD mutation and/or uracilemia >16ng/mL and/or homozygous UGT1A1 genotype.
- •Pregnancy, breastfeeding
- •Inability to sign informed consent or to undergo medical monitoring of the trial for geographical, social or psychological reasons including, but not limited to, psychiatric illness compromising comprehension of information or conduct of the study.
- •Patient under guardianship, curatorship or safeguard of justice.
研究组 & 干预措施
FOLFIRINOX treatment
Experimental
Treatment with FOLFIRINOX3 will be administered with a maximum of 16 courses divided into two 8-course doses.
Maintenance treatment (folinic acid/calcium levofolinate + 5-FU) will be administered until progression.
干预措施: FOLFIRINOX treatment (Drug)
结局指标
主要结局
Progression-free survival (PFS)
时间窗: 6 months
Progression-free survival (PFS) on FOLFIRINOX3 at 6 months.
次要结局
- Overall survival (OS)(24 months)
- Acute and late toxicities (adverses events)(Until 30 days after the end of treatment)
- Quality of life (QoL)(Until the end of treatment an average of 14 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic CancerMetastatic Pancreatic CancerNCT02028806Yuhong Li40
已完成
2 期
Efficacy and Safety of mFOLFIRINOX as Postoperative Chemotherapy for Pancreatic Cancer in Chinese Patients.Pancreatic Cancer ResectableNCT04224402Yuhong Li80
已完成
2 期
FOLFOXIRI as Primary Treatment for Locally Advanced Pancreatic CancerPancreatic Carcinoma Stage IIINCT02351219Azienda Ospedaliero, Universitaria Pisana50
已完成
2 期
Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal CancerStomach NeoplasmsEsophageal NeoplasmsNCT01928290Washington University School of Medicine67
招募中
2 期
mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer PatientsPancreatic CancerNCT04084496Sun Yat-sen University80